| Theme |
How should we interpret sessile serrated adenoma/polyp ? |
| Title |
Is SSA/P neoplastic lesion ? |
| Author |
Tamotsu Sugai |
Division of Molecular Diagnostic Pathology, Department of Pathology School of Medicine, Iwate Medical University |
| Author |
Wataru Habano |
Department of Pharmacodynamics and Molecular Genetics, School of Pharmacy, Iwate Medical University |
| Author |
Hiro-o Yamano |
Department of Gastroenterology, Akita Red Cross Hospital |
| Author |
Eiichirou Yamamoto |
1st Department of Internal Medicine, Sapporo Medical University / Department of Molecular Biology, School of Medicine, Sapporo Medical University |
| Author |
Hiromu Suzuki |
Department of Molecular Biology, School of Medicine, Sapporo Medical University |
| [ Summary ] |
Previous data suggested that sessile serrated adenomas/polyps (SSA/P) are early precursor lesions in the serrated pathway of carcinogenesis. It is well known that SSA/Ps develop into cancers through an SSA/P-dysplasia-carcinoma sequence. It is unclear whether SSA/Ps are neoplastic or non-neoplastic lesions. SSA/Ps are characterized by BRAF mutations, CIMP (CpG islands methylated phenotype) and MSI (microsatellite instability). In relation to these molecular alterations, BRAF mutation is a commonly observed alteration in hyperplastic polyps, SSA/P and MSI-positive cancer (serrated pathway lesions). Furthermore, SSA/P has distinct histological features, such as dilatation of crypt bases. Those findings suggest that SSA/P is neoplastic in nature. |